Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

PubWeight™: 2.16^‹?› | Rank: Top 2%

🔗 View Article (PMID 26720632)

Published in JAMA Oncol on April 01, 2016

Authors

Maxine Sun¹, Toni K Choueiri², Ole-Petter R Hamnvik³, Mark A Preston¹, Guillermo De Velasco², Wei Jiang¹, Stacy Loeb⁴, Paul L Nguyen⁵, Quoc-Dien Trinh¹

Author Affiliations

1: Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
2: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
3: Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts4Adult Survivorship Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Ma.
4: New York University and Manhattan Veterans Affairs Medical Center, New York.
5: Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Articles citing this ↘

Association of Androgen Deprivation Therapy With Alzheimer's Disease: Unmeasured Confounders. J Clin Oncol (2016) 0.81

Orchiectomy has fewer adverse effects than chemical castration for metastatic prostate cancer. BMJ (2015) 0.75

Chemical or Surgical Castration-Is This Still an Important Question? JAMA Oncol (2016) 0.75

Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial. J Urol (2016) 0.75

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study. Jpn J Clin Oncol (2017) 0.75

Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis. Onco Targets Ther (2017) 0.75

Articles by these authors ⇆

Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. JAMA (2015) 1.27

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer (2016) 0.76